WEST LAFAYETTE, Ind., March 25, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases, announced today that it will hold its 2011 Annual Meeting of Stockholders on Thursday, May 26, 2011, in Indianapolis, Indiana. 

The record date for the Annual Meeting will be April 11, 2011. Only stockholders of record at the close of business on April 11, 2011, may vote at the meeting. Endocyte anticipates making its proxy statement available to these stockholders in April 2011, which will include the time and location of the Annual Meeting, as well as a description of the matters to be considered.

About Endocyte

Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. Endocyte uses its proprietary technology to create novel small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized targeted therapies. The company's SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently, and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging diagnostics are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.
CONTACT: Vickey Buskirk, Endocyte Inc.         (765) 807-0617         Stephanie Ascher, Stern Investor Relations, Inc.         (212) 362-1200

If you liked this article you might like

Focused on Stock Picking Through This Volatility

Focused on Stock Picking Through This Volatility

Closing Bell; Endocyte Spikes: LIVE MARKETS BLOG

Closing Bell; Endocyte Spikes: LIVE MARKETS BLOG

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

A Small Biotech Sells for Less Than Cash

A Small Biotech Sells for Less Than Cash

A Small, but Promising Biotech Stock

A Small, but Promising Biotech Stock